Zobrazeno 1 - 10
of 147
pro vyhledávání: ''
Autor:
Stefano Stabile, Constantin Volovat, Piotr Koralewski, Krassimir Koynov, Iulian Bobe, Adina Croitoru, Juneko E. Grilley Olson, Tudor-Eliade Ciuleanu, Giulio Cerea, Atsushi Osada, Simona Ruxandra Volovat
Publikováno v:
Oncotarget
NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity,
Autor:
Akihiro Takeuchi, Masaki Nakamura, Hideki Motobayashi, Toshiyasu Ojima, Shimpei Maruoka, Shinta Tominaga, Keiji Hayata, Naoki Fukuda, Junya Kitadani, Mikihito Nakamori, Hiroki Yamaue, Masahiro Katsuda
Publikováno v:
Oncotarget
Background Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation (AF) after esophagectomy for esophageal cancer in our previous randomized controlled trial (RCT). In addition, reduced incid
Autor:
Jannick Brennum, Christina Westmose Yde, Vibeke Andrée Larsen, Jane Skjøth-Rasmussen, Ulrik Lassen, Lise Barlebo Ahlborn, Petra Hamerlik, Olga Østrup, Finn Cilius Nielsen, Signe Regner Michaelsen, Hans Skovgaard Poulsen, Dorte Schou Nørøxe
Publikováno v:
Oncotarget
Nørøxe, D S, Østrup, O, Yde, C W, Ahlborn, L B, Nielsen, F C, Michaelsen, S R, Larsen, V A, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Poulsen, H S & Lassen, U 2019, ' Cell-free DNA in newly diagnosed patients with glioblastoma-a clinical prospective feasibility study ', OncoTarget, vol. 10, no. 43, pp. 4397-4406 . https://doi.org/10.18632/oncotarget.27030
Nørøxe, D S, Østrup, O, Yde, C W, Ahlborn, L B, Nielsen, F C, Michaelsen, S R, Larsen, V A, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Poulsen, H S & Lassen, U 2019, ' Cell-free DNA in newly diagnosed patients with glioblastoma-a clinical prospective feasibility study ', OncoTarget, vol. 10, no. 43, pp. 4397-4406 . https://doi.org/10.18632/oncotarget.27030
// Dorte Schou Noroxe 1 , 2 , Olga Ostrup 3 , Christina Westmose Yde 3 , Lise Barlebo Ahlborn 3 , Finn Cilius Nielsen 3 , Signe Regner Michaelsen 1 , Vibeke Andree Larsen 4 , Jane Skjoth-Rasmussen 5 , Jannick Brennum 5 , Petra Hamerlik 6 , Hans Skovg
Autor:
Ashok Sharma, Ritu Gupta, Neerja Bhatla, Sunesh Kumar, Lalit Kumar, Minakshi Mann, Sachin Kumar, Sameer Bakhshi, Shyam S. Chauhan
Publikováno v:
Oncotarget
Cisplatin is a keystone for treatment of both recurring and locally advanced cervical cancer. However toxic side effects and acquired resistance limits its efficacy. Enhanced DNA repair is one of the mechanisms through which cancer cells acquire cisp
Autor:
Takahisa Furuta, Moriya Iwaizumi, Takahiro Suzuki, Haruhiko Sugimura, Yasushi Hamaya, Shinya Tani, Hiroaki Miyajima, Takahiro Uotani, Ken Sugimoto, Satoshi Osawa, Takuma Kagami, Mihoko Yamade, Satoshi Baba
Publikováno v:
Oncotarget
// Takuma Kagami 1 , Mihoko Yamade 1 , Takahiro Suzuki 1 , Takahiro Uotani 1 , Shinya Tani 2 , Yasushi Hamaya 1 , Moriya Iwaizumi 3 , Satoshi Osawa 2 , Ken Sugimoto 1 , Satoshi Baba 4 , Haruhiko Sugimura 5 , Hiroaki Miyajima 1 and Takahisa Furuta 6 1
Autor:
Hanna Voropaev, Maria Gimmelshein, Nathalie Cassoux, Dudi Shneor, Shay Tayeb, Alik Honigman, Shahar Frenkel, Jacob Pe'er
Publikováno v:
Oncotarget
Uveal melanoma (UM) is the most frequent intraocular tumor in adult patients. When metastases occur, systemic therapy with alkylating agents (fotemustine or dacarbazine (DTIC)) has shown only modest efficacy. The common chemotherapeutic drug doxorubi
Autor:
Ricardo Costa, Alfred Rademaker, Benedito A. Carneiro, Corinne H. Miller, Manali Bhave, Jason B. Kaplan, Sarah M. Talamantes, Young Kwang Chae, R. Costa, Devalingam Mahalingam
Publikováno v:
Oncotarget
// Rubens Barros Costa 1 , Ricardo L.B. Costa 2 , Sarah M. Talamantes 3 , Jason B. Kaplan 1 , Manali A. Bhave 1 , Alfred Rademaker 4 , Corinne Miller 5 , Benedito A. Carneiro 6 , Devalingam Mahalingam 1 and Young Kwang Chae 1 1 Developmental Therapeu
Autor:
Eugenio Ragazzi, Daniela Catanzaro, Veronica Cocetta, Silvia Nicolosi, Monica Montopoli, Gianfranco Pasut, Andrea Pagetta, Marika Salvalaio
Publikováno v:
Oncotarget
Ovarian cancer is an aggressive and lethal cancer usually treated by cytoreductive surgery followed by chemotherapy. Unfortunately, after an initial response, many patients relapse owing mainly to the development of resistance against the standard ch
Autor:
Qiong Zhou, Amanda B. Pilling, Aik Choon Tan, Jihye Kim, Katherine R. Singleton, Anh T. Le, James DeGregori, Adriana Estrada-Bernal, Lynn E. Heasley, Robert C. Doebele
Publikováno v:
Oncotarget
// Amanda B. Pilling 1,2 , Jihye Kim 1 , Adriana Estrada-Bernal 1 , Qiong Zhou 1 , Anh T. Le 1 , Katherine R. Singleton 1 , Lynn E. Heasley 1 , Aik Choon Tan 1 , James DeGregori 1 and Robert C. Doebele 1 1 University of Colorado Cancer Center, Aurora
Publikováno v:
Oncotarget
Treatment for ovarian cancer remains challenging despite a high initial response rate to first line platinum-taxane treatment. Most patients eventually experience recurrence and require further treatment. Persistent activation of STAT3 is associated